Nephron

Nephrology Grand Rounds. Clinical Issues in Nephrology
Section Editors: Prof. E. Ritz and Dr. M. Zeier, Heidelberg

Tacrolimus in Kidney Transplantation

A Clinical Review

Kliem V. · Brunkhorst R.

Author affiliations

Abteilung Nephrologie,Medizinische Hochschule Hannover, Deutschland

Related Articles for ""
Nephron 1998;79:8–20
https://doi.org/10.1159/000044985

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

Published online: April 29, 1998
Issue release date: May 1998

Number of Print Pages: 13
Number of Figures: 1
Number of Tables: 2

ISSN: 1660-8151 (Print)
eISSN: 2235-3186 (Online)

For additional information: https://www.karger.com/NEF


First-Page Preview
Abstract of Nephrology Grand Rounds. Clinical Issues in Nephrology<br>Section Editors: Prof. E. Ritz and Dr. M. Zeier, Heidelberg


Related Articles:

References

  1. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, Kohsaka M, Aoki H, Imanaka H: FK-506, a novel immunosuppressant isolated from a Streptomyces. Antibiotics 1987;40:1249–1255.
  2. Peters DH, Fitton A, Plosker GL, Faulds D: Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993;46:746–794.
    External Resources
  3. Mayer AD, Dmitrewski J, Squifflet J-P, Besse T, Grabensee B, Klein B, Eigler F, Heemann U, Pichlmayr R, Behrend M, Vanrenterghem Y, Donck J, van Hooff J, Christiaans M, Morales JM, Andres A, Johnson RWG, Short C, Buchholz B, Rehmert N, Land W, Schleibner S, Forsythe JLR, Talbot D, Neumayer H-H, Hauser I, Ericzon B-G, Brattström C, Claesson K, Mühlbacher F, Pohanka E: Multicenter randomized trial comparing tacrolimus (FK-506) and cyclosporine in the prevention of renal allograft rejection. Transplantation 1997;64:436–443.
    External Resources
  4. Schreiber SL: Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 1991;251:283–287.
    External Resources
  5. Schreiber SL, Crabtree GR: The mechanism of action of cyclosporin A and FK-506. Immunol Today 1992;13:136–142.
    External Resources
  6. Bierer BE, Somers PK, Wandless TJ, Burakoff SJ, Schreiber SL: Probing immunosuppressant action with a nonnatural immunophilin ligand. Science 1990;250:556–559.
    External Resources
  7. Bierer BE, Mattila PS, Standaert RF, Herzenberg LA, Burakoff SJ, Crabtree G, Schreiber SL: Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK-506 or rapamycin. Proc Natl Acad Sci USA 1990;87:9231–9235.
    External Resources
  8. DeFranco AL: Immunosuppressants at work. Nature 1991;352:754–755.
    External Resources
  9. Wang T, Li BY, Danielson PD, Shah PC, Rockwell S, Lechleider RJ, Martin J, Manganaro T, Donahoe PK: The immunophilin FKBP-12 functions as a common inhibitor of the TGF-β family type I receptors. Cell 1996;86:435–444.
    External Resources
  10. Shihab FS, Tanner AM, Shao Y, Weffer MI: Expression of TGF-β1 and matrix proteins is elevated in rats with chronic rejection. Kidney Int 1996;50:1904–1913.
    External Resources
  11. Winkler M, Christians U: A risk-benefit assessment of tacrolimus in transplantation. Drug Safety 1995;12:348–357.
    External Resources
  12. Japanese FK-506 Study Group: Japanese Study of FK-506 on kidney transplantation: The benefit of monitoring the whole blood FK-506 concentration. Transplant Proc 1991;23:3085–3088.
    External Resources
  13. Christians U, Kruse C, Kownatzki R, Schiebel HM, Schwinzer R, Sattler M, Schottmann R, Linck A, Almeida VMF, Braun F, Sewing K-F: Measurement of FK-506 by HPLC and isolation and characterization of its metabolites. Transplant Proc 1991;23:940–941.
    External Resources
  14. Christians U, Braun F, Kosian N, Schmidt M, Schiebel HM, Ernst L, Kruse C, Winkler M, Holze I, Linck A, Sewing K-F: High-performance liquid chromatography/mass spectrometry of FK-506 and its metabolites in blood, bile, and urine of liver grafted patients. Transplant Proc 1991;23:2741–2744.
    External Resources
  15. Mekki Q, Lee C, Aweeka F, Laskow D, Neylan J, Mendez R, Steinmuller D, Schechter P: Pharmacokinetics of tacrolimus (FK-506) in kidney transplant patients (abstract). Clin Pharmacol Ther 1993;53:238.
  16. Christians U, Guengerich FP, Schmidt G, Sewing K-F: In-vitro metabolism of FK-506, cytochrome P450 and drug interactions (abstract). Ther Drug Monit 1993;15:145.
  17. Pirsch J, Bekersky I, Vincenti F, Woodle ES, Alak A, Kruelle M, Boswell G, Mekki Q: Co-administration of tacrolimus and mycophenolate mofetil may result in higher MPA exposure (abstract). Abstr 16th Annual Meeting of American Society of Transplant Physicians, Chicago, May 10–14, 1997, p 133.
  18. Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, Esquenazi V, Burke G, Tzakis A, Miller J: Augmentation of mycophenolate mofetil pharmacokinetics in renal transplant patients receiving Prograf and Cellcept in combination therapy. Transplant Proc 1997;29:334–336.
    External Resources
  19. Japanese FK-506 Study Group: Japanese study of FK-506 on kidney transplantation: Results of an early phase II study. Transplant Proc 1991;23:3071–3074.
    External Resources
  20. Japanese FK-506 Study Group: Japanese study of FK-506 on kidney transplantation: Results of late phase II study. Transplant Proc 1993;25:649–654.
    External Resources
  21. Shapiro R, Jordan M, Scantlebury V, Fung J, Jensen C, Tzakis A, McCauley J, Carroll P, Ricordi C, Demetris AJ, Mitchell S, Jain A, Iwaki Y, Kobayashi M, Reyes J, Todo S, Hakala TR, Simmons RL, Starzl TE: FK-506 in clinical kidney transplantation. Transplant Proc 1991;23:3056–3067.
  22. Shapiro R, Jordan ML, Scantlebury VP, Fung JJ, Jensen C, Vivas C, McCauley J, Irish WD, Mitchell S, Demetris AJ, Randhawa P, Jain A, Tzakis A, Hakala TR, Simmons RL, Starzl TE: Randomized trial of FK-506/prednisolone vs. FK-506/azathioprine/prednisone after renal transplantation: Preliminary report. Transplant Proc 1993;25:669–672.
    External Resources
  23. Vincenti F, Laskow DA, Neylan JF, Mendez R, Matas AJ: One-year follow-up of an open-label trial of FK-506 for primary kidney transplantation. Transplantation 1996;61:1576–1581.
    External Resources
  24. Schleibner S, Krauss M, Wagner K, Erhard J, Christiaans M, van Hooff J, Buist L, Mayer D: FK-506 versus cyclosporin in the prevention of renal allograft rejection – European pilot study: six-week results. Transplant Int 1995;8:86–90.
    External Resources
  25. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS for the FK-506 Kidney Transplant Study Group: A comparison of tacrolimus (FK-506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997;63:977–983.
    External Resources
  26. Mayer AD, Salsbury J, Squifflet JP, Grabensee B, Eigler W, Behrend M, Vanrenterghem Y, van Hooff JP, Morales JM, Johnson RWG, Buchholz B, Land W, Talbott D, Hauser I, Ericzon BG, Mühlbacher F: Second-year follow-up from the European tacrolimus (FK506) multicentre renal study (abstract). International Congress on Immunosuppression, Orlando, Dec 1997, p 123.
  27. Jensik SC, for the FK506 Kidney Transplant Study Group: Tacrolimus (FK506) in kidney transplantation: Three-year survival results of the US multicenter, randomized, comparative study (abstract). International Congress on Immunosuppression, Orlando, Dec 1997, p 123.
  28. Jordan ML, Shapiro R, Jensen CWB, Scantlebury V, Fung J, Tzakis A, McCauley J, Jain A, Demetrius J, Randhawa P, Simmons RL, Hakala TR, Starzl TE: FK-506 conversion of renal allografts failing cyclosporine immunosuppression. Transplant Proc 1991;23:3078–3081.
    External Resources
  29. Jordan ML, Shapiro R, Vivas CA, Scantlebury VP, Rhandhawa P, Carrieri G, McCauley J, Demetris AJ, Tzakis A, Fung JJ, Simmons RL, Hakala TR, Starzl TE: FK-506 ‘rescue’ for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 1994;57:860–865.
    External Resources
  30. Woodle S, Josephson MA, Newell KA, Piper JB, Millis JM, Bruce DS, Whitman G, Ruebe M, Thistlethwaite JR: FK-506 rescue therapy for renal allograft rejection: Experience with an aggressive approach (abstract). Abstr 14th Annual Meeting of the American Society of Transplant Physicians, 1995.
  31. Eberhard OK, Kliem V, Oldhafer K, Schlitt HJ, Pichlmayr R, Koch KM, Brunkhorst R: How best to use tacrolimus (FK-506) for treatment of steroid- and OKT3-resistant rejection after renal transplantation. Transplantation 1996;61:1345–1349.
    External Resources
  32. Felldin M, Bäckman I, Brattström C, Bentdal Ö, Nordal K, Claesson K, Persson NH: Rescue therapy with tacrolimus (FK-506) in renal transplant recipients – A Scandinavian multicenter analysis. Transplant Int 1997;10:13–18.
    External Resources
  33. Ochiai T, Ishibashi M, Fukao K, Takahashi K, Endo T, Yokoyama I, Uchida K, Ohshima S, Takahara S, Morozumi K, Yamaguchi Y, Kyo M, Sonoda T, Takagi H, Ota K, Iwasaki Y, the Japanese FK-506 Study Group: Japanese multicenter studies of FK-506 in renal transplantation. Transplant Proc 1995;27:50–53.
    External Resources
  34. Kliem V, Schaumann D, Ehlerding G, Eberhard O, Lufft V, Schlitt HJ, Pichlmayr R, Koch KM, Brunkhorst R: Long-term results after primary successful FK-506 treatment of steroid or OKT3-resistant rejection in renal transplant recipients. Transplant Proc 1997;29:2955–2957.
    External Resources
  35. Shapiro R, Scantlebury VP, Jordan ML, Vivas C, Tzakis AG, Ellis D, Gilboa N, Hopp L, McCauley J, Irish W, Mitchell S, Hakala TR: FK-506 in pediatric kidney transplantation – Primary and rescue experience. Pediatr Nephrol 1995;9:43–48.
  36. Latta K, Offner G, Oldhafer K, Müller T, Hoyer PF, Brodehl J: Tacrolimus nach Nierentransplantation bei Kindern (abstract). Transplantationsmedizin 1994(suppl):19.
  37. Greenstein SM, Tellis VA, Corey H: Improved pediatric renal transplant graft survival with FK-506 rescue therapy (abstract). Abstr 14th Annual Meeting of American Society of Transplant Physicians, 1995.
  38. Burke GW, Alejandro R, Roth D, Colona J, Contreras N, Ciancio G, Skyler JS, Ricordi C, Nery J, Tzakis A, Miller J: Use of FK-506 in simultaneous pancreas/kidney transplantation: Lack of impairment of glycemic or lipid metabolism. Transplant Proc 1995;27:3119–3120.
    External Resources
  39. Hariharan S, Peddi VR, Munda R, Demmy AM, Schroeder TJ, Alexander JW, First MR: Long-term renal and pancreas function with tacrolimus rescue therapy following kidney/pancreas transplantation. Transplant Proc 1997;29:652–653.
    External Resources
  40. Gruessner RWG, Burke GW, Stratta R, Sollinger H, Benedetti E, Marsh C, Stock P, Boudreaux JP, Martin M, Drangstveit MB, Sutherland DER, Gruessner A: A multicenter analysis of the first experience with FK-506 for induction and rescue therapy after pancreas transplantation. Transplantation 1996;61:261–273.
    External Resources
  41. European FK-506 Multicentre Liver Study Group: Randomised trial comparing tacrolimus (FK-506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994;344:423–428.
    External Resources
  42. Fung JJ, Alessiani M, Abu-Emagd K, Todo S, Shapiro A, Tzakis A, Van Thiel D, Armitage J, Jain A, McCauley J, Selby R, Starzl TE: Adverse effects associated with the use of FK-506. Transplant Proc 1991;23:3105–3108.
    External Resources
  43. Atkison P, Joubert G, Barron A, Grant D, Paradis K, Seidman E, Wall W, Rosenberg H, Howard J, Williams S, Stiller C: Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet 1995;345:894–896.
    External Resources
  44. Yamada K, Sugisaki Y, Akimoto M, Yamanaka N: FK-506-induced juxtaglomerular apparatus hyperplasia and tubular damage in rat kidney – morphologic and biologic analysis. Transplant Proc 1992;24:1396–1398.
    External Resources
  45. Moutabarrik A, Ishibashi M, Fukunaga M, Kameoka H, Kawaguchi N, Takano Y, Kokado Y, Sonoda T, Onishi S, Takahara S, Okuyama A: FK-506-induced kidney tubular cell injury. Transplantation 1992;54:1041–1047.
    External Resources
  46. McCauley J, Fung JJ, Todo S, Jain A, Deballi P, Starzl TE: Changes in renal function after liver transplantation under FK-506. Transplant Proc 1991;23:3143–3145.
    External Resources
  47. McCauley J: The nephrotoxicity of FK-506 as compared with cyclosporine. Nephrol Hypertens 1993;2:662–669.
    External Resources
  48. Randhawa PS, Shapiro R, Jordan ML, Starzl TE, Demetris AJ: The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK-506. Clinical significance and comparison with cyclosporine. Am J Surg Pathol 1993;17:60–68.
    External Resources
  49. Devlin J, Williams R, Neuhaus P, McMaster P, Calne R, Pichlmayr R, Otto G, Bismuth H, Groth C: Renal complications and development of hypertension in the European study of FK-506 and cyclosporin in primary liver transplant recipients. Transplant Int 1994;7(suppl 1):22–26.
    External Resources
  50. Platz KP, Müller AR, Blumhardt G, Bachmann S, Bechstein W-O, Kahl A, Neuhaus P: Nephrotoxicity following orthotopic liver transplantation. Transplantation 1994;58:170–178.
    External Resources
  51. Singh N, Gayowski T, Marino IR: Hemolytic uremic syndrome in solid-organ transplant recipients. Transplant Int 1996;9:68–75.
    External Resources
  52. Schmidt RJ, Venkat KK, Dumler F: Hemolytic-uremic syndrome in a renal transplant recipient on FK-506 immunosuppression. Transplant Proc 1991;23:3156–3157.
    External Resources
  53. Kaufman DB, Kaplan B, Kanwar YS, Abecassis M, Stuart FP: The successful use of tacrolimus (FK-506) in a pancreas/kidney transplant recipient with recurrent cyclosporine-associated hemolytic uremic syndrome. Transplantation 1995;59:1737–1739.
    External Resources
  54. Abdalla AH, Al-Sulaiman MH, Al-Khader AA: FK-506 as an alternative in cyclosporin-induced hemolytic uremic syndrome in a kidney transplant recipient. Transplant Int 1994;7:382–384.
    External Resources
  55. Armitage JM, Kormos RL, Fung J, Lavee J, Fricker FJ: Preliminary experience with FK-506 in thoracic transplantation. Transplantation 1991;52:164–167.
    External Resources
  56. Textor SC, Wiesner R, Wilson DJ, Porayko M, Romero JC, Burnett JCJ, Gores G, Hay E, Dickson ER, Krom RA: Systemic and renal hemodynamic differences between FK-506 and cyclosporine in liver transplant recipients. Transplantation 1993;55:1332–1339.
    External Resources
  57. Radermacher J, Meiners M, Bramlage C, Kliem V, Behrend M, Schlitt HJ, Pichlmayr R, Koch KM, Brunkhorst R: Pronounced renal vasoconstriction and systemic hypertension by cyclosporine compared to FK-506 in renal transplant patients. Transplant Int 1998;11:3–10.
    External Resources
  58. Benigni A, Morigi M, Perico N, Zoja C, Amuchastegui CS, Piccinelli A, Donadelli R, Remuzzi G: The acute affect of FK-506 and cyclosporine on endothelial function and renal vascular resistance. Transplantation 1992;54:775–780.
    External Resources
  59. Mor E, Sheiner PA, Schwartz ME, Emre S, Guy S, Miller CM: Reversal of severe FK 506 side effects by conversion to cyclosporine-based immunosuppression. Transplantation 1994;58:380–382.
    External Resources
  60. Hytiroglu P, Lee R, Sharma K, Theise ND, Schwartz M, Miller C, Thung SN: FK-506 versus cyclosporine as primary immunosuppressive agent for orthotopic liver allograft recipients. Transplantation 1993;56:1389–1394.
    External Resources
  61. Fisher A, Mor E, Hytiroglou P, Emre S, Boccagni P, Chodoff L, Sheiner P, Schwartz M, Thung SN, Miller C: FK-506 hepatotoxicity in liver allograft recipients. Transplantation 1995;59:1631–1632.
    External Resources
  62. Lufft V, Kliem V, Behrend M, Pichlmayr R, Koch KM, Brunkhorst R: Incidence of Pneumocystis carinii pneumonia after renal transplantation. Transplantation 1996;62:421–423.
    External Resources
  63. Cox LK, Lawrence-Miyasaki LS, Garcia-Kennedy R, Lennette ET, Martinez OM, Krams SM, Berquist WE, So SKS, Esquivel CO: An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK-506 after liver transplantation. Transplantation 1995;59:524–529.
    External Resources
  64. Shapiro R, Scantlebury VP, Jordan ML, Vivas C, Gritsch HA, Ellis D, Gilboa N, Lombardozzi-Lane S, Irish W, Fung JJ, Hakala TR, Simmons RL, Starzl TE: Tacrolimus in pediatric renal transplantation. Transplantation 1996;62:1752–1758.
    External Resources
  65. Hirano Y, Fujihira S, Ohara K, Katsuki S, Noguchi H: Morphological and functional changes of islets of Langerhans in FK-506-treated rats. Transplantation 1992;53:889–894.
    External Resources
  66. Carroll PB, Boschero AC, Li M-Y, Tzakis AG, Starzl TE, Atwater I: Effect of the immunosuppressant FK-506 on glucose-induced insulin secretion from adult rat islets of Langerhans. Transplantation 1991;51:275–277.
    External Resources
  67. Jindal RM: Posttransplant diabetes mellitus – A review. Transplantation 1994;58:1289–1298.
    External Resources
  68. Frei U, Schindler R, Wieters D, Brunkhorst R, Koch KM: Pretransplant hypertension: A major risk factor for chronic progressive renal allograft dysfunction? Nephrol Dial Transplant 1995;10:1206–1212.
    External Resources
  69. Basadonna GP, Matas AJ, Gillingham KJ, Payne WD, Dunn DL, Sutherland DER, Gores PF, Gruessner RWG, Najarian JS: Early versus late acute renal allograft rejection: Impact on chronic rejection. Transplantation 1993;55:993–995.
    External Resources
  70. Weir MR, Anderson L, Fink JC, Schweitzer E, Hoehn-Saric E, Klassen D, Cangro CM, Kuo P, Johnson L, Lim J, Barlett ST: A new approach to the treatment of chronic allograft nephropathy (abstract). Abstr 16th Annual Meeting of the American Society of Transplant Physicians, Chicago, May 10–14, 1997, p 184.
  71. Meiser BM, Überführ P, Martin S, Fuchs A, Schulze C, von Scheidt W, Angermann C, Kreuzer E, Reichart B: Initial intravenous administration of tacrolimus improves the long-term results after transplantation (abstract). J Heart and Lung Transplant 1997;16:45.
  72. Pichlmayr R, Bismuth H, Calne R, Groth C, McMaster P, Neuhaus P, Otto G, Williams R: Three-year data from the European multicentre tacrolimus liver study (abstract). Abstr XVI International Congress of the Transplantation Society, Barcelona, August 25–30, 1996, p 185.
  73. Platz KP, Mueller AR, Haller GW, Berg T, Neuhaus R, Bechstein W-O, Hopf U, Lobeck H, Neuhaus P: Impact of immunosuppression and acute rejection on hepatitis B recurrence. Transplant Proc 1997;29:509–510.
    External Resources

Article / Publication Details

Published online: April 29, 1998
Issue release date: May 1998

Number of Print Pages: 13
Number of Figures: 1
Number of Tables: 2

ISSN: 1660-8151 (Print)
eISSN: 2235-3186 (Online)

For additional information: https://www.karger.com/NEF

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

1998, Vol.79, No. 1

May 1998

Article

Recommend This
Additional Information

Place of Grand Rounds: University of Heidelberg, Germany
TOP